Atley Solutions

Alpha Therapy Solutions is a pioneering startup in the pharmaceutical industry, specializing in the development and production of astatine-related pharmaceuticals. The company's primary focus is on Targeted Alpha Therapy (TAT), a potentially curative and less toxic alternative to standard cancer treatments. TAT uses astatine-211 (At-211), a radioactive isotope, to deliver highly targeted and less toxic local irradiation of cancer cells.

Alpha Therapy Solutions' flagship product, the Atley C100 module, is the world's first commercial production module capable of both purifying At-211 from cyclotron targets and synthesizing At-211 based radiopharmaceuticals in an automated process. This automation technology streamlines the production process, making it more efficient and cost-effective.

The company serves a broad range of clients, including pharmaceutical companies, research institutions, and healthcare providers. Its business model is based on selling its products and providing development services to assist clients in their At-211 pharmaceutical development projects. This includes everything from At-211 access, drug discovery, and development, to commercialization.

Founded by two leading astatine radiochemists, Alpha Therapy Solutions has carved out a unique niche in the market. It has created a clear commercialization pathway for radiopharmaceuticals based on astatine-211, positioning itself as a key player in the future of cancer treatment.

Keywords: Alpha Therapy Solutions, astatine-211, Targeted Alpha Therapy, Atley C100 module, pharmaceutical development, automated production, cancer treatment, drug discovery, drug commercialization, radiopharmaceuticals.